Last reviewed · How we verify
NCT05906407: COGNITION
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
trial testing Genomic Profiling / Sequencing in Early-Stage Breast Cancer in 2,000 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | German Cancer Research Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 19 April 2019 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 12 locations across Germany |
Drugs / interventions tested
- Genomic Profiling / Sequencing
Conditions studied
- Early-Stage Breast Cancer — all drugs for Early-Stage Breast Cancer →
- Neoadjuvant Therapy — all drugs for Neoadjuvant Therapy →
Sponsor
German Cancer Research Center — full company profile →
Who can join
Adults 18 to 80, any sex, with Early-Stage Breast Cancer or Neoadjuvant Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients. The major goal is to provide a framework for genomic profiling, which serves as infrastructure for systematic biomarker-screening and -stratification for concise therapy-arm allocation in the interventional clinical phase II trial COGNITION-GUIDE (NCT05332561). In patients, who display a poor response to standard-of-care neoadjuvant chemotherapy, tissue samples before and after neoadjuvant therapy are subjected together with blood samples to comprehensive genomic profiling to identify patients potentially benefiting from biomarker-guided interventions in COGNITION-GUIDE. Samples not required for standard-of-care clinical procedures or genomic profiling are systematically collected in a dedicated bio-repository to fuel translational scientific companion programs. The continuously growing comprehensive database serves as an integrative resource for systematic, prospective multidimensional data collection (clinical records, biomaterial, genomic data). In summary, the overarching goal is to generate a precision oncology platform i) to identify clinically-actionable biomarkers and drug targets that drive genomics-guided therapies and ii) to couple the observational, diagnostic registry platform to the independent, biomarker-stratified clinical therapy trial COGNITION-GUIDE.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05906407
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Genomic Profiling / Sequencing
Trials testing the same drug.
- NCT05652569 — CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer · recruiting
Other recruiting trials for Early-Stage Breast Cancer
Currently open trials in the same condition.
- NCT06970912 — ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · recruiting
Other German Cancer Research Center trials
Trials by the same sponsor.
- NCT06614673 — Cancer Literacy as an Essential Factor for Lifestyle Behavior Changes: An Observational and Interventional Study · NA · completed
- NCT06026384 — Evaluation of Text or Animation-based Narrative and Non-narrative Interventions to Enhance Cancer Literacy: a Pilot Stud · NA · completed
- NCT05999396 — FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer · Phase 1 · recruiting
- NCT05494866 — A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal · Phase 1 · terminated
- NCT06621810 — Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05906407 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by German Cancer Research Center
- Last refreshed: 19 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05906407.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing